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S U M M A R Y
Background: Data are scarce on ocular complications in Egyptian patients with chronic hepatitis C treated
with pegylated interferon and ribavirin therapy. The aim of this study was to investigate the
development of retinal lesions induced by interferon therapy for chronic hepatitis C.
Methods: We prospectively analyzed 84 patients with chronic hepatitis C (total 168 eyes), who underwent
combination pegylated interferon and ribavirin therapy for 48 weeks. Visual acuity, color vision, and visual
ﬁeld were measured, and a fundus assessment was made at baseline, at 12, 24, and 48 weeks post the
commencement of treatment, and at follow-up, 1 month after treatment. Past medical and ocular histories,
visual symptoms, and the results of a full ophthalmologic assessment were recorded for each patient.
Results: Twenty-two patients (26%) developed retinopathy. Retinal hemorrhage was observed in eight
patients. Four patients complained of visual disturbance. Retinopathy disappeared in 16 patients (73%)
despite the continuation of combination therapy. However, retinopathy persisted in six patients with
retinal hemorrhage and three of them stopped treatment. A comparison of the clinical backgrounds
between the patients with and without retinopathy showed no signiﬁcant differences with regard to
gender, HCV RNA level, white blood cell count, platelet count, hemoglobin level, or ﬁbrosis score.
However patients with retinopathy were of older age, had a higher prevalence of hypertension and
diabetes mellitus, and more often did not respond to therapy. Multiple logistic regression analysis
revealed that hypertension and diabetes were factors predicting retinopathy.
Conclusion: Retinopathy associated with interferon a-2a and ribavirin combination therapy tends to
develop in patients of older age with hypertension and diabetes.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The primary aim of antiviral therapy in patients with chronic
hepatitis C is a sustained virological response (SVR), deﬁned as
undetectable serum hepatitis C virus (HCV) RNA by a sensitive
molecular assay at 24 weeks after the end of treatment.
Combination therapy with pegylated interferon (peginterferon)
and ribavirin is currently recognized as the standard treatment of
chronic hepatitis C, resulting in an SVR rate of 40–50% in patients
infected with HCV genotypes 1 and 4, and around 80% in those
infected with HCV genotypes 2 and 3.1–3
Various adverse effects have been reported due to the use of
interferon. An inﬂuenza-like syndrome, characterized by fever,
chills, myalgias, arthralgias, and headache, is the most common
adverse effect. Toxicities of the central nervous, hematopoietic,* Corresponding author.
E-mail address: Yasserfouad10@yahoo.com (Y.M. Fouad).
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doi:10.1016/j.ijid.2011.09.022gastrointestinal, urinary, cardiovascular, musculoskeletal, and
endocrine systems have also been described. However, ocular
toxicity was not reported before the use of interferon for chronic
hepatitis.4 The association of HCV infection and retinopathy has
been described in the literature. The reported ophthalmic
manifestations of HCV infection are keratoconjunctivitis sicca,
ischemic retinopathy, macular edema, and ischemic neuropa-
thy.5–7
Following the introduction of interferon for the treatment of
hepatitis, retinal complications have been reported with a higher
prevalence in patients with diabetes. Typical ocular lesions include
cotton-wool spots and retinal hemorrhages at the posterior
fundus, particularly around the optic disc. Cotton-wool spots
and retinal hemorrhages may occur alone or together. Retinal
hemorrhages appear as superﬁcial linear and patchy forms, or as
white-centered bleeding. The retinopathy may develop unilater-
ally or bilaterally. Blocking of background ﬂuorescence by retinal
hemorrhages and non-perfused areas at the cotton-wool spots can
be seen by ﬂuorescein angiography.8ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Ophthalmologic manifestations in chronic hepatitis C patients treated with
peginterferon–ribavirin therapy (Combined: cotton-wool spots and hemorrhage;
Hge, retinal hemorrhage; AION, anterior ischemic optic neuropathy). Data are
presented as the number of patients.
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proportion of patients undergoing interferon monotherapy devel-
op retinopathy.9–11 However, the prevalence of retinopathy is
variable, which is presumably attributed to the difference in the
treatment regimen and/or background of patients.
In interferon–ribavirin combination therapy, diabetes, hyper-
tension, and response to treatment12,13 have been considered
possible risk factors. However, the results are not conclusive
because of the small number of patients examined, as they have
been from case reports and case series.14–18 The aim of this study
was to investigate the development of retinal lesions induced by
interferon therapy for chronic hepatitis C and to retrospectively
analyze the risk factors.
2. Materials and methods
This study was undertaken at the virology and ophthalmology
clinics of Minia University Hospital, Minia, Egypt from January
2009 to January 2011. Patients with histologically conﬁrmed
chronic hepatitis C by liver biopsy and who fulﬁlled the criteria for
treatment were enrolled in this study. Liver biopsy results and the
METAVIR score were recorded for every patient. All patients were
treated weekly with 180 mg subcutaneous peginterferon a-2a and
oral ribavirin at a total daily dose of 1000–1400 mg according to
body weight.
Serum HCV RNA was detected by qualitative reverse-transcrip-
tion polymerase chain reaction (RT-PCR; Amplicor HCV, Roche
Diagnostics). The serum HCV load was determined by quantitative
RT-PCR (Amplicor HCV Monitor Test, version 2.0, Roche Diagnos-
tics). HCV RNA genotyping was performed using a second-
generation line probe assay (LiPA; Innogenetics, Brussels, Belgium).
The end-of-treatment response (ETR) was assessed by qualita-
tive PCR assay. ETR was deﬁned as an undetectable serum HCV RNA
level at the end of treatment. A non-responder was deﬁned by the
presence of viremia (less than 2 log reduction) at 12 weeks, or 24
weeks, or at the end of therapy.
3. Ophthalmologic examination
All patients were examined by an expert ophthalmologist at our
hospital. The ophthalmologist was not blinded to patient baseline
clinical data (e.g., diabetes, hypertension). The optic fundi were
examined before therapy was started, at 12, 24, and 48 weeks after
the start of treatment, and at 4 weeks after the end of treatment.
Patients with a pretreatment abnormal fundus examination were
excluded from the study. The ophthalmologic examination includ-
ed: visual acuity assessment using Landolt C rings optotype, fundus
examination using an indirect ophthalmoscope, and pupillary
reaction examination (for direct and indirect light reﬂex, and
swinging ﬂash light test). When retinal abnormalities were detected,
colored fundus photographs were obtained and ﬂuorescence
angiography carried out for documentation and comparison. Data
recorded included visual complaints, visual acuity, pupillary
reactions, and retinal ﬁndings.
The study was approved by the ethics committee of our centers
and was carried out in accordance with the Declaration of Helsinki
and the guidelines of the International Conference on Harmoniza-
tion for Good Clinical Practice. All patients provided written
informed consent before enrollment.
4. Statistical analysis
Data entry and analysis were all done with an IBM compatible
computer using SPSS software version 13 (SPSS, Chicago, IL, USA).
Results were expressed as mean  standard deviation (SD), median
(interquartile range), or number (%). Comparisons between the meanand median values were done using the unpaired t-test and Mann–
Whitney test. Comparisons between categorical data (n (%)) were
done using the Chi-square test. Logistic regression analysis was
performed to determine the risk factors. A p-value of 0.05 was
considered signiﬁcant; <0.01 was considered highly signiﬁcant.
5. Results
Of 560 patients with chronic hepatitis C attending our clinic, 240
were treated with peginterferon–ribavirin therapy. One hundred
and sixteen consecutive patients fulﬁlled the criteria for our study,
but only 84 patients agreed to participate. Sixty-one of these patients
were males and 23 were females; their median age was 43.4 years
(range 24–55 years). All patients had HCV genotype 4.
At the end of peginterferon–ribavirin combination therapy, 59
(70%) patients had an ETR and 25 (30%) patients were non-
responders. Twenty-two out of 84 patients (26%) developed
retinopathy at various time-points. The retinopathy ﬁndings were
predominantly cotton-wool spots, followed by retinal hemorrhage
(Figure 1). On ﬂuorescence angiography, all patients with cotton-
wool spots showed areas of capillary non-perfusion, signifying
retinal ischemia, and areas of blocked ﬂuorescence in the case of
retinal hemorrhage.
Other ocular manifestations included anterior ischemic optic
neuropathy (AION) in two cases, optic neuritis in one patient,
abnormal color vision in six patients, diminished visual acuity in four
patients, and abnormal pupillary reaction in three patients
(Figure 1).
We compared the characteristics of patients who developed
retinopathy and those who did not. There were no statistically
signiﬁcant differences between the two groups with regard to
gender, HCV RNA level, white blood cell count, platelet count,
hemoglobin level, or ﬁbrosis score before treatment (Table 1). The
patients with retinopathy were signiﬁcantly older. Hypertension,
diabetes, and non-response to therapy were more prevalent in
patients who developed retinopathy. Retinal hemorrhages were
not more common in those with METAVIR scores of 3–4 or with
underlying coagulopathies.
Logistic regression analysis of factors affecting retinopathy was
also carried out. Hypertension and diabetes were found to be
factors predicting retinopathy (Table 2).
Table 1
Characteristics of patients with and without retinopathy during peginterferon–ribavirin combination therapy
Retinopathy (n = 22) No retinopathy (n = 62) p-Value
Age (years), mean  SD 48.8  6.2 41.7  8.2 <0.05
Sex female, n (%) 7 (32%) 16 (26%) 0.59
ALT level, median (IQR) 34 (5–120) 52 (12–95) 0.1196
HCV RNA (copies/ml), median (IQR) 35 490 (11 760–300 000) 34 640 (5500–300 000) 0.123
Fibrosis METAVIR score, n (%)
F1–F2 15 (68%) 42 (68%) 1.00
F3–F4 7 (32%) 20 (32%)
Hemoglobin (mg/dl), mean  SD 11.7  1.3 11.3  1.6 0.15
Neutrophil count (cells  109/l), median (IQR) 2.55 (1.10–5.70) 2.30 (1.30–19.00) 0.82
Platelet count (cells  109/l), median (IQR) 110.50 (67.00–180.00) 115.00 (60.00–1100.00) 0.76
Diabetes mellitus, n (%) 13 (59%) 3 (5%) <0.0001
Hypertension, n (%) 9 (41%) 3 (5%) 0.0002
Response to treatment, n (%)
Responder 9 (59%) 50 (81%) 0.0002
Non-responder 13 (41%) 12 (19%)
SD, standard deviation; ALT, alanine aminotransferase; IQR, interquartile range; HCV, hepatitis C virus.
Table 2
Logistic regression analysis of factors associated with retinopathy
Variable OR 95% CI p-Value
Age 1.65 0.84–3.23 0.14
Sex 0.47 0.006–34.9 0.73
Hemoglobin 192.89 0.0–1.1 0.89
White blood cell count 0.14 0.0–57.5 0.52
ALT 0.459 0.3–1.5 0.14
Platelets 208.4 0.1–1.9 0.16
Viral load 0.214 0.12–1.4 0.1
Liver ﬁbrosis 0.26 0.008–8.7 0.45
Diabetes mellitus 0.002 0.0–1.4 0.05
Hypertension 3.6 4–6.6 0.001
Response to therapy 0.2 0.03–2.1 0.09
OR, odds ratio; CI, conﬁdence interval; ALT, alanine aminotransferase.
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improved on ophthalmologic treatment. Six patients continued to
have retinopathy while on ophthalmologic treatment, and three of
these patients discontinued interferon therapy at their request
(Table 3).
Table 4 shows the clinical course of the 22 patients with
retinopathy during peginterferon–ribavirin therapy. The retinopa-
thy ﬁndings were predominantly cotton-wool spots, followed by
retinal hemorrhage.
Regarding color vision abnormalities, six patients were
recorded to have abnormal color vision using pseudoisochromatic
plates (Ishihara plates, n = 12): two patients with mild impairment
(10/12; 11/12), two patients with moderate impairment (7/12;
8/12), and the last two patients had anterior ischemic optic
neuropathy with severe impairment (2/12; 3/12).
The abnormal pupillary reactions included a partial afferent
pupillary defect in which there is a paradoxical pupillary reaction,
as the abnormal pupil shows initial dilatation instead of
constriction on exposure to pen torch light by swinging reﬂex,
and this abnormal reaction signiﬁes optic nerve abnormality, as in
the case of anterior ischemic optic neuropathy detected in two
cases in this study (Figure 2).Table 3
Follow-up of patients with retinopathy, from onset until the follow-up after treatment
Baselinea At 12 week
Number of patients with retinopathy 0 8 
Improvedb 0 7 
Continuedc 0 1 
a Baseline: before beginning interferon.
b Improved with treatment and follow-up by an ophthalmologist.
c Continued: persistent retinopathy after the end of treatment.6. Discussion
It has been hypothesized that interferon-a therapy may cause
deposition of immune complexes in the retinal vasculature.
Leukocyte inﬁltration with subsequent retinal ischemia could
then lead to capillary non-perfusion and thus cotton-wool spot
formation.19 Cotton-wool spots are not generally the cause of
visual compromise, but they are a signiﬁcant ﬁnding because they
can be indicative of an underlying vascular disease, such as
diabetes mellitus or hypertension. Retinal hemorrhages do not
usually cause signiﬁcant visual disturbance, but occasionally
acuity may be affected because of a macular hemorrhage. There
is evidence that interferon inhibits the proliferation and migration
of vascular endothelial cells in vitro, and it has demonstrated the
ability to inhibit experimental intraocular neovascularization.20–22
The frequency of retinopathy associated with peginterferon–
ribavirin combination therapy in the present study was 26%. The
frequencies reported in other studies range from 16% to 64%.12,13,22
It appears that there may be geographic differences in the
incidence of interferon-associated retinopathy. The frequencies
noted in recent reports from the UK have been as low as 0% (in a
prospective study23) and 3.8% (in a retrospective study24). In the
ﬁrst study 42 men and 10 women were followed. No patients
reported any subjective visual symptoms and no patient developed
optic disc changes or permanent fundus changes over the follow-
up period. In the second study, of 183 patients, 29 (16%) had
diabetes and 85 (46%) had hypertension. Seven (3.8%) had retinal
changes on follow-up, and treatment was discontinued in three
(1.6%). Of the seven with ocular changes, two had hypertension and
one had both hypertension and diabetes. In Southeast Asia, the
frequencies of retinopathy have been reported as 34.4%25 and
100%.26 In the ﬁrst study 11 of 32 patients (34.4%) developed
retinopathy. Cotton-wool spots were found in six patients, retinal
hemorrhages in four, and branch retinal vein occlusion in one (one
eye). Hypertension was found to be the most signiﬁcant risk factor
for developing retinopathy. In the second study, all of the patients
(six patients) developed a soft retinal exudate and ﬁve developed
retinal blot hemorrhage.s At 24 weeks At 48 weeks At follow-up
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Table 4
Clinical course of each patient with retinopathy during peginterferon–ribavirin therapy
Patient Age, years Sex Underlying disease Response to therapy Ocular manifestations after treatment (time of discovery) Course
Hypertension Diabetes mellitus
1 42 M + + NR Cotton-wool spots and diminished visual acuity (24 weeks) Persistence of ocular ﬁndings
2 55 M – + R Cotton-wool spots (48 weeks) Recovery of ocular manifestations
3 32 F – – NR Cotton-wool spots and retinal hemorrhage; abnormal pupillary reaction (12 weeks) Recovery of ocular manifestations
4 54 M + + R Cotton-wool spots (12 weeks) Recovery of ocular manifestations
5 49 F – + NR Optic neuritis and retinal hemorrhage (12 weeks) Severe visual impairment
6 42 M + + NR Cotton-wool spots (24 weeks) Recovery of ocular manifestations
7 46 M + + NR Cotton-wool spots (24 weeks) Recovery of ocular manifestations
8 51 M – + R Cotton-wool spots and abnormal color vision (48 weeks) Recovery of ocular manifestations
9 53 M – + NR Cotton-wool spots (12 weeks) Recovery of ocular manifestations
10 51 M – – R Cotton-wool spots and diminished visual acuity (24 weeks) Recovery of ocular manifestations
11 51 M + + R Cotton-wool spot and abnormal color vision (24 weeks) Recovery of ocular manifestations
12 54 M + + NR Cotton-wool spot and retinal hemorrhage (12 weeks) Recovery of ocular manifestations
13 55 M – – NR Cotton-wool spots and diminished visual acuity (48 weeks) Recovery of ocular manifestations
14 55 F + – R Cotton-wool spots and abnormal pupillary reaction (48 weeks) Recovery of ocular manifestations
15 47 F – + NR Retinal hemorrhage and AION (12 weeks) Recovery of ocular manifestations
16 52 M + – R Cotton-wool spots (12 weeks) Recovery of ocular manifestations
17 47 F – + R Cotton-wool spots (12 weeks) Recovery of ocular manifestations
18 47 M – – NR Retinal hemorrhage and abnormal pupillary reaction (48 weeks) Minimal visual impairment
19 49 M – – R Cotton-wool spots and abnormal color vision (24 weeks) Minimal visual impairment
20 38 F – – NR Retinal hemorrhage and diminished visual acuity (48 weeks) Mild impairment of the visual acuity
21 46 F – + NR Cotton-wool spots and retinal hemorrhage (48 weeks) Recovery of ocular manifestations
22 39 M + – NR Retinal hemorrhage and AION (24 weeks) Signiﬁcant visual loss
M, male; F, female; NR, non-responder; R, responder; AION, anterior ischemic optic neuropathy.
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Y.M. Fouad et al. / International Journal of Infectious Diseases 16 (2012) e67–e71 e71examination of the optic fundi, major retinal complications may be
prevented or at least detected earlier. Therefore, patients who
undergo interferon–ribavirin combination therapy, particularly
those with hypertension, diabetes, or of older age should undergo
periodic examination of the optic fundi.
To conclude, the incidence of retinopathy associated with
combination pegylated interferon plus ribavirin therapy in our
locality tends to be higher than that reported in the USA and
Europe and lower than that reported in Asia. Hypertension,
diabetes, and older age put the patient at higher risk of retinopathy
induced by antiviral therapy. We recommend careful ophthalmo-
logic monitoring in these patients.
Conﬂict of interest: No conﬂict of interest to declare.
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